Sun | Nov 28, 2021

Merck asks FDA to authorise promising anti-COVID pill

Published:Tuesday | October 12, 2021 | 12:08 AM
An undated image provided by Merck & Company of their new antiviral experimental pill for people sick with COVID-19.
An undated image provided by Merck & Company of their new antiviral experimental pill for people sick with COVID-19.

Drugmaker Merck asked United States regulators on Monday to authorise its pill for treating COVID-19 in what would add an entirely new and easy-to-use weapon to the world’s arsenal against the pandemic.

If cleared by the Food and Drug Administration – a decision that could come in a matter of weeks – it would be the first pill shown to treat the illness. All other FDA-backed treatments against COVID-19 require an IV or injection.

An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload on US hospitals and helping to curb outbreaks in poorer countries with weak healthcare systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.

The FDA will scrutinise company data on the safety and effectiveness of the drug, molnupiravir, before rendering a decision.

Merck and its partner Ridgeback Biotherapeutic said they specifically asked the agency to grant emergency use for adults with mild to moderate COVID-19 who are at risk for severe disease or hospitalisation. That is roughly the way COVID-19-infusion drugs are used.

“The value here is that it’s a pill, so you don’t have to deal with the infusion centres and all the factors around that,” said Dr Nicholas Kartsonis, a senior vice-president with Merck’s infectious disease unit. “I think it’s a very powerful tool to add to the toolbox.”

The company reported earlier this month that the pill cut hospitalisations and deaths by half among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.

Side effects were similar between patients who got the drug and those in a testing group, who received a dummy pill. But Merck has not publicly detailed the types of problems reported, which will be a key part of the FDA’s review.

Top US health officials continue to push vaccinations as the best way to protect against COVID-19.

“It’s much, much better to prevent yourself from getting infected than to have to treat an infection,” Dr Anthony Fauci said while discussing Merck’s drug last week.

Still, some 68 million eligible Americans remain unvaccinated, underscoring the need for effective drugs to control future waves of infection.

The prospect of a COVID-19 pill comes amid other encouraging signs: New cases per day in the US have dropped below 100,000 on average for the first time in over two months, and deaths are running at about 1,700 a day, down from more than 2,000 three weeks ago.

Also, the average number of vaccinations dispensed per day has climbed past one million, an increase of more than 50 per cent over the past two weeks, driven by the introduction of booster shots and workplace vaccine requirements.

Still, heath authorities are bracing for another possible surge as cold weather drives more people indoors.

Since the beginning of the pandemic, health experts have stressed the need for a convenient pill. The goal is for something similar to Tamiflu, the 20-year-old flu medication that shortens the illness by a day or two and blunts the severity of symptoms like fever, cough and stuffy nose.

Three FDA-authorised antibody drugs have proved highly effective at reducing COVID-19 deaths, but they are expensive, hard to produce, and require specialty equipment and health professionals to deliver.

Assuming FDA authorisation, the US government has agreed to buy enough of the pills to treat 1.7 million people, at a price of roughly US$700 for each course of treatment. That’s less than half the price of the antibody drugs purchased by the US government – over US$2,000 per infusion – but still more expensive than many antiviral pills for other conditions.

Merck’s Kartsonis said in an interview that the US$700 figure does not represent the final price for the medication.

“We set that price before we had any data, so that’s just one contract,” Kartsonis said. “Obviously, we’re going to be responsible about this and make this drug as accessible to as many people around the world as we can.”

Kenilworth, New Jersey-based Merck has said it is in purchase talks with governments around the world and will use a sliding price scale based on each country’s economic means. Also, the company has signed licensing deals with several Indian generic drugmakers to produce low-cost versions of the drug for lower-income countries.

AP